

This promotional material has been developed and funded by Bayer plc and is intended for UK healthcare professionals only. Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. Prescribing information and adverse event reporting statement for Kerendia can be accessed via a OR code located at the bottom of this document.



The Silent Epidemic Early CKD Detection for Kidney and Diabetes Health

Kidney disease is a public health emergency in the UK



People with CKD stages 3-51

The total annual

economic burden

of CKD1,2

2023 ~3.25 million

£7 billion

IN THE UK IN

BY 2033 THIS COULD RISE TO

3.9 million

£13.9 billion

healthcare interventions could save 10,000 lives by 2033 and would be cost-effective1,2

Implementing kidney-related



Earlier and improved diagnosis of CKD



Adults and children on dialysis due to kidney failure1

30,000

143,000





Kidney transplants per year¹

~3,000 12.000

Rising economic and healthcare burden of CKD are expected across a ten year period unless urgent action is taken



Fictional case study

Anne is a 65-year-old female.

She has had T2D for 25 years:

- eGFR: 55 mL/min/1.73m2 (Stage 3a CKD)
- uACR: 26 mg/mmol
- Taking ARB and SGLT2i



Better adherence to clinical guidelines



Increased uptake of new medicines for managing CKD

Empower and educate patients with T2D about their kidney health as many do not recognise the importance of regular kidney function tests.

Act early in Kerendia eligible patients like Anne and delay CKD progression in T2D3* In the FIDELIO-DKD study, Kerendia showed a sustained reduction in CKD progression compared to placebo^{3,4}



Add Kerendia to your standard of care for your CKD-associated T2D patients

NICE recommends Kerendia® (finerenone), the first and only UK licensed non-steroidal MRA, as an add-on to standard of care for stage 3 and 4 CKD (with albuminuria) associated with T2D6**

Kerendia® (finerenone) slows CKD progression in T2D and can significantly delay progression of renal disease (vs. placebo)4

Diabetic kidney disease is progressive and irreversible; act now with Kerendia® (finerenone) to significantly reduce the risk of renal & CV events for your patients (vs. placebo)4

**Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.3

*CKD progression defined as the first occurrence of composite of onset of kidney failure, or sustained decrease of eGFR ≥40% from baseline over at least 4 weeks or death due to renal causes.⁴
*Refer to relevant SGLT2i SmPC before prescribing due to variability in licenses.

‡If in line with NICE recommendation and within licence.

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; MRA, mineralocorticoid receptor antagonist; NICE, National Institute for Health and Care Excellence; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SmPC, Summary of Product Characteristics; T2D, type 2 diabetes; uACR, urinary albumin:creatinine ratio; UK, United Kingdom.

unnary albumin:creatinine ratio; UK, United Kingdom.

1. Kidney Research UK, Kidney disease: A UK public health emergency – The health economics of kidney disease to 2033. June 2023. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf. Accessed November 2024; 2. Kidney-Besearch UK. Kidney disease is a public health emergency that threatens to overhelm the NHS, major new report reveals. June 2023. Available at: https://www.kidneyresearchuk.org/2023/06/05/kidney-disease-is-a-public-health-emergency-that-threatens-to-overwhelm-the-nhs-major-new-report-reveals/. Accessed November 2024; 3. Kerendia SmPC; 4. Bakris GL, et al. N Eng.J Med 2020;383:2219–2229; 5. NICE. Type 2 diabetes in adults: management [NG28]. Available at: https://www.nice.org.uk/guidance/ta877. Accessed November 2024; 6. NICE.

Prescribing information for Kerendia®▼ (finerenone) is available via the QR code on the right.

Either click here or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure that your device's browser settings have automatic PDF download enabled

